Constipation

Key messages

Clinical practice guidelines from the EAPC are as follows: [1]

  • Constipation in palliative care is fundamentally defined by the patient.
  • If the patient complains of constipation, has reduced frequency of defecation or difficulty with defecation, assessment of bowel habits is warranted.
  • A thorough patient history and physical examination are essential.
  • A checklist of key facts should be used to assess causative factors and impact of constipation – this assessment should be continuous throughout the patient’s care.
  • If malignant intestinal obstruction is suspected, this should be investigated by radiology.
  • Preventative measures such as ensuring privacy and comfort, encouraging activity and increasing fluid intake should be ongoing during the patient’s care.
  • Rectal intervention for the relief of constipation should be avoided where possible, but may be necessary where oral medication has been unsuccessful in re-establishing a regular bowel pattern.
  • Generally, a combination of a softener (eg, polyethylene glycol and electrolytes or lactulose) and a stimulant (eg, senna or sodium picosulphate) laxative is recommended.

  

  

  

PubMed Searches

Constipation
Free full text only All citations About these searches
Review Collection

Prophylactic co-prescribing of regular laxatives along with regular opioids is identified as best practice. [1-3]

In palliative care patients there is a limit to the potential for prevention and management of constipation by dietary, lifestyle or preventive strategies, and these should not be solely relied upon. [1]

Evidence Summary

Definition and Prevalence

Constipation has been defined as 'the passage of small, hard faeces infrequently and with difficulty'. Individuals vary in the weight they give to the different components of this definition when assessing their own constipation and may introduce other factors, such as pain and discomfort when defecating, flatulence, bloating or a sensation of incomplete evacuation.' [1] Constipation is a frequent complaint in the general community, and more common in palliative care patients. [4-6] Chronic constipation is one of the commonest side effects of all opioids and occurs in 40 – 70 per cent of patients treated for cancer pain with oral morphine. [7] However other causes of constipation should also be sought and addressed. [4]

Assessment

Opioid induced constipation should be considered during the assessment of constipation. Other possible contributing factors include:

  • Medications – 5-HT3 antagonists, anticholinergics, iron, some antihypertensives
  • Decreased oral intake, dehydration, alterations in diet
  • Metabolic abnormalities (eg, hypercalcaemia, uraemia, hypothyroidism, hypokalaemia, diabetes)
  • Decreased mobility, weakness, difficulty accessing toilet facilities
  • Bowel obstruction
  • Neurological disorder or damage, eg, due to spinal cord lesion
  • Autonomic neuropathy
  • Depression
  • Terminal phase.

Despite the prevalence of constipation in palliative care patients, it is underdiagnosed and undertreated. [5] Examination of the patient should include a focused rectal examination, including assessment of the pelvic floor and anorectal structures. Abdominal radiology may be needed to exclude obstruction, but is not required to make a diagnosis. [1]

Treatment

As well as addressing and modifying any possible causes of constipation, laxatives are usually required. The evidence base supporting the choice of any specific laxative is not strong, either for the general population, [8,9] or specifically in a palliative care population. [1,10] However, general recommendations for prevention and treatment of constipation in palliative care patients have been made based on expert opinion, and these suggest the combination of a stimulant and a softening agent is usually required. [1]

Rectal interventions may also be necessary when impaction has occurred, when there is a neuropathic cause for the problem, or when there is a myopathy. This needs to be assessed on an individual basis. Treatment of constipation is addressed in more detail in the sub-section on Pharmacological management.

Evidence Gap

  • One of the difficulties in researching constipation is the lack of a consensus definition. [6] The EAPC definition relies on the patient’s own subjective assessment of whether or not they are constipated, rather than on frequency of defecation. [1] There are considerable differences between individuals, which make it difficult to propose a general description of normal and abnormal bowel habits. [4] As a result, research on the prevalence of constipation and on the outcomes of treatment is difficult to interpret.
  • Clinical studies of new drugs for the management of opioid induced bowel dysfunction are ongoing. Several novel opioid antagonists which have only local effects on the gastrointestinal tract, including methylnaltrexone, have shown promise in clinical trials. [11-13] Methylnaltrexone may have additional benefits in improving gastric emptying, however further research is needed. [14,15]
  • Other newer potential pharmacological approaches to managing chronic constipation include selective calcium channel agonists (lubiprostone) or 5HT3 serotonin receptor agonists (tegaserod). These agents are not available in Australia and have not yet been studied in the palliative care population. [16]
  • A relationship between deteriorating performance status, opioids, anticholinergic load, proximity of death, and the prescription of laxatives has been suggested. [17]

 

  1. Larkin P, Sykes NP, Centeno C, Ellershaw JE, Elsner F, Eugene B, et al. The management of constipation in palliative care: clinical practice recommendations. Palliat Med. 2008 Oct;22(7):796-807.
  2. Palliative Care Expert Group. Therapeutic guidelines: palliative care. Version 3. Melbourne: Therapeutic Guidelines Limited; 2010.
  3. NHS Quality Improvement Scotland (NHS QIS). Best Practice Statement - The management of pain in patients with cancer. Edinburgh: NHS QIS; 2009 Nov.
  4. Davis MP. Cancer constipation: are opioids really the culprit? Support Care Cancer. 2008 May;16(5):427-9. Epub 2008 Jan 15.
  5. Droney J, Ross J, Gretton S, Welsh K, Sato H, Riley J. Constipation in cancer patients on morphine. Support Care Cancer. 2008 May;16(5):453-9. Epub 2008 Jan 16.
  6. Muldrew DHL, Hasson F, Carduff E, Clarke M, Coast J, Finucane A, et al. Assessment and management of constipation for patients receiving palliative care in specialist palliative care settings: A systematic review of the literature. Palliat Med. 2018 May;32(5):930-938. doi: 10.1177/0269216317752515. Epub 2018 Feb 12.
  7. Cherny N, Ripamonti C, Pereira J, Davis C, Fallon M, McQuay H, et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001 May 1;19(9):2542-54.
  8. Jones MP, Talley NJ, Nuyts G, Dubois D. Lack of objective evidence of efficacy of laxatives in chronic constipation. Dig Dis Sci. 2002 Oct;47(10):2222-30.
  9. Alsalimy N, Madi L, Awaisu A. Efficacy and safety of laxatives for chronic constipation in long-term care settings: A systematic review. J Clin Pharm Ther. 2018 Oct;43(5):595-605. doi: 10.1111/jcpt.12721. Epub 2018 Jun 9.
  10. Candy B, Jones L, Larkin PJ, Vickerstaff V, Tookman A, Stone P. Laxatives for the management of constipation in people receiving palliative care. Cochrane Database Syst Rev. 2015 May 13;(5):CD003448. doi: 10.1002/14651858.CD003448.pub4.
  11. Becker G, Galandi D, Blum HE. Peripherally acting opioid antagonists in the treatment of opiate-related constipation: a systematic review. J Pain Symptom Manage. 2007 Nov;34(5):547-65. Epub 2007 Sep 27.
  12. Thomas J. Opioid-induced bowel dysfunction. J Pain Symptom Manage. 2008 Jan;35(1):103-13. Epub 2007 Nov 5.
  13. McNicol ED, Boyce D, Schumann R, Carr DB. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006332. doi: 10.1002/14651858.CD006332.pub2.
  14. Gatti A, Sabato AF. Management of Opioid-Induced Constipation in Cancer Patients: Focus on Methylnaltrexone. Clin Drug Investig. 2012 May 1;32(5):293-301. doi: 10.2165/11598000-000000000-00000.
  15. Candy B, Jones L, Vickerstaff V, Larkin PJ, Stone P. Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care. Cochrane Database Syst Rev. 2018 Jun 5;6:CD006332. doi: 10.1002/14651858.CD006332.pub3.
  16. Thomas J. Cancer-related constipation. Curr Oncol Rep. 2007 Jul;9(4):278-84.
  17. Clark K, Lam LT, Agar M, Chye R, Currow DC. The impact of opioids, anticholinergic medications and disease progression on the prescription of laxatives in hospitalized palliative care patients: a retrospective analysis. Palliat Med. 2010 Jun;24(4):410-8. Epub 2010 Mar 26.

Last updated 23 October 2019